Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
      Google Scholar   
Citation:
J Thorac Oncol vol 3 (10) 1159-65
Year:
2008
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
631  
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
CA03927, CA114558-02, CA21060, CA31946, CA31983, CA33601, CA35113, CA35421, CA37447, CA41287, CA45389, CA45418, CA45564, CA45808, CA47559, CA47577, CA47642, CA74811, CA77298, CA77440  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
CALGB-30303
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Adenocarcinoma, Adenocarcinoma, Bronchiolo-Alveolar, Adult, Aged, Anemia, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Darbepoetin alfa, Dose-Response Relationship, Drug, Drug Therapy, Combination, Erythropoietin, Feasibility Studies, Female, Filgrastim, Granulocyte Colony-Stimulating Factor, Hematinics, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Mesna, Middle Aged, Neoplasm Staging, Neutropenia, Polyethylene Glycols, Prognosis, Recombinant Proteins, Survival Rate, Taxoids